3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
13
Phase 1
4
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
11
Breast
11
Thoracic
8
Genitourinary
7
Gastrointestinal
5
CNS
3
Tumor-Agnostic
2
Other solid neoplasm
2
NET
2
Endocrine
2
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Conditions
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Temozolomide
33
Radiotherapy
32
pembrolizumab
18
Cyclophosphamide
18
Irinotecan
16
Gemcitabine
16
Doxorubicin
16
Nivolumab
11
Docetaxel
11
Sirolimus
10
Imatinib Mesylate
10
Ifosfamide
10
Filgrastim
10
Radiation
9
Bevacizumab
9
Vincristine
8
Carboplatin
8
pazopanib
7
Everolimus
7
temsirolimus
6
atezolizumab
6
Peripheral Blood Stem Cell Transplantation
6
Etoposide
6
fludarabine phosphate
5
Vorinostat
5
Specimen Handling
5
Radiotherapy, Conformal
5
PM 01183
5
Ipilimumab
5
Erlotinib Hydrochloride
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
olaparib
×
Sarcoma
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled